Royal Bank Of Canada Oncorus, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $0.45 $0 - $1	-3 Reduced 1.32%	225 $0
Q4 2022 Feb 14, 2023	BUY	$0.24 - $0.76 $0 - $2	3 Added 1.33%	228 $0
Q3 2022 Nov 14, 2022	BUY	$0.85 - $1.65 $80 - $156	95 Added 73.08%	225 $0
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.86 $1,170 - $2,092	-1,125 Reduced 89.64%	130 $0
Q1 2022 May 16, 2022	SELL	$1.44 - $5.62 $4,285 - $16,725	-2,976 Reduced 70.34%	1,255 $2,000
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $7,600 - $17,572	1,511 Added 55.55%	4,231 $23,000
Q3 2021 Nov 15, 2021	BUY	$9.29 - $14.27 $12,272 - $18,850	1,321 Added 94.42%	2,720 $25,000
Q2 2021 Aug 16, 2021	BUY	$13.3 - $17.3 $18,606 - $24,202	1,399 New	1,399 $19,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.